Clinical Trial

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated July 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-06; most recent amendment 2024-09-27.
Trial Details
NCT Number NCT06499233
Lead Sponsor Tongji Hospital
Conditions Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases, Connective Tissue Disease, Prevention
Enrollment 800 participants
Start Date 2024-07-20
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01